Tags

Type your tag names separated by a space and hit enter

Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial.
Can J Psychiatry. 2013 Jul; 58(7):402-8.CJ

Abstract

OBJECTIVE

To investigate whether long-chain omega-3 (n-3) polyunsaturated fatty acids (PUFAs) improve functioning and psychiatric symptoms in young people with borderline personality disorder (BPD) who also meet ultra-high risk criteria for psychosis.

METHODS

We conducted a post hoc subgroup analysis of a double-blind, randomized controlled trial. Fifteen adolescents with BPD (mean age 16.2 years, [SD 2.1]) were randomized to either 1.2 g/day n-3 PUFAs or placebo. The intervention period was 12 weeks. Study measures included the Positive and Negative Syndrome Scale, the Montgomery-Åsberg Depression Rating Scale, and the Global Assessment of Functioning. Side effects were documented with the Udvalg for Kliniske Undersøgelser. Fatty acids in erythrocytes were analyzed using capillary gas chromatography.

RESULTS

At baseline, erythrocyte n-3 PUFA levels correlated positively with psychosocial functioning and negatively with psychopathology. By the end of the intervention, n-3 PUFAs significantly improved functioning and reduced psychiatric symptoms, compared with placebo. Side effects did not differ between the treatment groups.

CONCLUSIONS

Long-chain n-3 PUFAs should be further explored as a viable treatment strategy with minimal associated risk in young people with BPD. (

CLINICAL TRIAL REGISTRATION NUMBER

NCT00396643).

Links

Publisher Full Text

Authors+Show Affiliations

Amminger GP
Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria. amminger@unimelb.edu.au
Chanen AM
No affiliation info available
Ohmann S
No affiliation info available
Klier CM
No affiliation info available
Mossaheb N
No affiliation info available
Bechdolf A
No affiliation info available
Nelson B
No affiliation info available
Thompson A
No affiliation info available
McGorry PD
No affiliation info available
Yung AR
No affiliation info available
Schäfer MR
No affiliation info available

MeSH

AdolescentBorderline Personality DisorderCoconut OilDocosahexaenoic AcidsDrug CombinationsEicosapentaenoic AcidFatty Acids, Omega-3FemaleHumansMalePlacebosPlant OilsPsychiatric Status Rating ScalesPsychotic DisordersRiskTreatment OutcomeVitamin EVitamins

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23870722

Clinical Trial Links

Clinical trial which this article describes

Citation

Amminger, G Paul, et al. "Omega-3 Fatty Acid Supplementation in Adolescents With Borderline Personality Disorder and Ultra-high Risk Criteria for Psychosis: a Post Hoc Subgroup Analysis of a Double-blind, Randomized Controlled Trial." Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, vol. 58, no. 7, 2013, pp. 402-8.
Amminger GP, Chanen AM, Ohmann S, et al. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Can J Psychiatry. 2013;58(7):402-8.
Amminger, G. P., Chanen, A. M., Ohmann, S., Klier, C. M., Mossaheb, N., Bechdolf, A., Nelson, B., Thompson, A., McGorry, P. D., Yung, A. R., & Schäfer, M. R. (2013). Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 58(7), 402-8.
Amminger GP, et al. Omega-3 Fatty Acid Supplementation in Adolescents With Borderline Personality Disorder and Ultra-high Risk Criteria for Psychosis: a Post Hoc Subgroup Analysis of a Double-blind, Randomized Controlled Trial. Can J Psychiatry. 2013;58(7):402-8. PubMed PMID: 23870722.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. AU - Amminger,G Paul, AU - Chanen,Andrew M, AU - Ohmann,Susanne, AU - Klier,Claudia M, AU - Mossaheb,Nilufar, AU - Bechdolf,Andreas, AU - Nelson,Barnaby, AU - Thompson,Andrew, AU - McGorry,Patrick D, AU - Yung,Alison R, AU - Schäfer,Miriam R, PY - 2013/7/23/entrez PY - 2013/7/23/pubmed PY - 2013/8/28/medline KW - adolescents KW - borderline personality disorder KW - omega-3 fatty acids KW - randomized controlled trial KW - ultra-high risk SP - 402 EP - 8 JF - Canadian journal of psychiatry. Revue canadienne de psychiatrie JO - Can J Psychiatry VL - 58 IS - 7 N2 - OBJECTIVE: To investigate whether long-chain omega-3 (n-3) polyunsaturated fatty acids (PUFAs) improve functioning and psychiatric symptoms in young people with borderline personality disorder (BPD) who also meet ultra-high risk criteria for psychosis. METHODS: We conducted a post hoc subgroup analysis of a double-blind, randomized controlled trial. Fifteen adolescents with BPD (mean age 16.2 years, [SD 2.1]) were randomized to either 1.2 g/day n-3 PUFAs or placebo. The intervention period was 12 weeks. Study measures included the Positive and Negative Syndrome Scale, the Montgomery-Åsberg Depression Rating Scale, and the Global Assessment of Functioning. Side effects were documented with the Udvalg for Kliniske Undersøgelser. Fatty acids in erythrocytes were analyzed using capillary gas chromatography. RESULTS: At baseline, erythrocyte n-3 PUFA levels correlated positively with psychosocial functioning and negatively with psychopathology. By the end of the intervention, n-3 PUFAs significantly improved functioning and reduced psychiatric symptoms, compared with placebo. Side effects did not differ between the treatment groups. CONCLUSIONS: Long-chain n-3 PUFAs should be further explored as a viable treatment strategy with minimal associated risk in young people with BPD. ( CLINICAL TRIAL REGISTRATION NUMBER: NCT00396643). SN - 0706-7437 UR - https://www.unboundmedicine.com/medline/citation/23870722/Omega_3_fatty_acid_supplementation_in_adolescents_with_borderline_personality_disorder_and_ultra_high_risk_criteria_for_psychosis:_a_post_hoc_subgroup_analysis_of_a_double_blind_randomized_controlled_trial_ L2 - https://journals.sagepub.com/doi/10.1177/070674371305800705?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -